Brain Tumor Initiating Cells Adapt to Restricted Nutrition through Preferential Glucose Uptake

Like all cancers, brain tumors require a continuous source of energy and molecular resources for new cell production. In normal brain, glucose is an essential neuronal fuel, but the blood-brain barrier limits its delivery. We now report that nutrient restriction contributes to tumor progression by enriching for brain tumor initiating cells (BTICs) owing to preferential BTIC survival and to adaptation of non-BTICs through acquisition of BTIC features. BTICs outcompete for glucose uptake by co-opting the high affinity neuronal glucose transporter, type 3 (Glut3, SLC2A3). BTICs preferentially express Glut3, and targeting Glut3 inhibits BTIC growth and tumorigenic potential. Glut3, but not Glut1, correlates with poor survival in brain tumors and other cancers; thus, tumor initiating cells may extract nutrients with high affinity. As altered metabolism represents a cancer hallmark, metabolic reprogramming may maintain the tumor hierarchy and portend poor prognosis.

[1]  Hui Wang,et al.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. , 2009, Cancer cell.

[2]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[3]  S. Cole,et al.  Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene , 2012 .

[4]  W. Robinson,et al.  Glucose as a fetal nutrient: dynamic regulation of several glucose transporter genes by DNA methylation in the human placenta across gestation. , 2013, The Journal of nutritional biochemistry.

[5]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[6]  M. Younes,et al.  Immunohistochemical detection of glut 3 in human tumors and normal tissues , 1997 .

[7]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[8]  L. Fellows,et al.  Rapid changes in extracellular glucose levels and blood flow in the striatum of the freely moving rat , 1993, Brain Research.

[9]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[10]  S. Grossman,et al.  Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Otto Warburn,et al.  THE METABOLISM OF TUMORS , 1931 .

[12]  S. Vannucci,et al.  Glucose transporter proteins in brain: Delivery of glucose to neurons and glia , 1997, Glia.

[13]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[14]  B. Shin,et al.  Creb1-Mecp2-(m)CpG complex transactivates postnatal murine neuronal glucose transporter isoform 3 expression. , 2013, Endocrinology.

[15]  P. Laird,et al.  Epigenetic stem cell signature in cancer , 2007, Nature Genetics.

[16]  H. Armah.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial , 2010 .

[17]  S. Nagamatsu,et al.  Expression of Facilitative Glucose Transporter Isoforms in Human Brain Tumors , 1993, Journal of neurochemistry.

[18]  Jayant P. Menon,et al.  Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.

[19]  J. Uhm.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[20]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[21]  D. Lee,et al.  Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer , 2004, Nuclear medicine communications.

[22]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[23]  G. Gould,et al.  The glucose transporter family: structure, function and tissue-specific expression. , 1993, The Biochemical journal.

[24]  R. McLendon,et al.  The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype , 2009, Cell cycle.

[25]  Eran Segal,et al.  Module map of stem cell genes guides creation of epithelial cancer stem cells. , 2008, Cell stem cell.

[26]  E. Mathews,et al.  High-glycolytic cancers and their interplay with the body's glucose demand and supply cycle. , 2011, Medical hypotheses.

[27]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[28]  A. Carvalho,et al.  Glut1 and Glut3 as Potential Prognostic Markers for Oral Squamous Cell Carcinoma , 2010, Molecules.

[29]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[30]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[31]  Mark A. Stephenson,et al.  Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survival , 1997, Cancer.

[32]  Gerald J. Sun,et al.  Neuronal circuitry mechanism regulating adult quiescent neural stem cell fate decision , 2012, Nature.

[33]  R. McLendon,et al.  Acidic stress promotes a glioma stem cell phenotype , 2011, Cell Death and Differentiation.

[34]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[35]  D. Muller,et al.  A simple method for organotypic cultures of nervous tissue , 1991, Journal of Neuroscience Methods.

[36]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[37]  S. Horvath,et al.  Neurosphere Formation Is an Independent Predictor of Clinical Outcome in Malignant Glioma , 2009, Stem cells.

[38]  B. Sylvén,et al.  Glucose, lactate, and lactic dehydrogenase activity in normal interstitial fluid and that of solid mouse tumors. , 1962, Cancer research.

[39]  A. Peters,et al.  The selfish brain: competition for energy resources , 2004, Neuroscience & Biobehavioral Reviews.

[40]  Subha Madhavan,et al.  Rembrandt: Helping Personalized Medicine Become a Reality through Integrative Translational Research , 2009, Molecular Cancer Research.

[41]  K. Oh,et al.  A novel fluorescent derivative of glucose applicable to the assessment of glucose uptake activity of Escherichia coli. , 1996, Biochimica et biophysica acta.

[42]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[43]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[44]  M. Younes,et al.  Immunohistochemical detection of Glut3 in human tumors and normal tissues. , 1997, Anticancer research.

[45]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[46]  A. Harris,et al.  Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. , 2001, Cancer research.

[47]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[48]  Juan Carlos Izpisua Belmonte,et al.  The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming , 2011, Cell Research.

[49]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[50]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[51]  K. Black,et al.  Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. , 1994, Brain research. Molecular brain research.

[52]  S. Baer,et al.  Glut3 Expression in Biopsy Specimens of Laryngeal Carcinoma Is Associated With Poor Survival , 2002, The Laryngoscope.

[53]  R. McLendon,et al.  Direct In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells , 2011, PloS one.

[54]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[55]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.